Thrombin-Receptor Antagonist Vorapaxar in Acute Coronary Syndromes
Pierluigi Tricoci(CSL (United States)), Kenneth W. Mahaffey(Cardiovascular Institute of the South), Petr Widimský(Universidad Americana), J. Wouter Jukema(Leiden University Medical Center), Basil S. Lewis(Technion – Israel Institute of Technology), Ángel Cequier(Bellvitge University Hospital), Lisa Jennings(University of Tennessee at Knoxville), Jan H. Cornel(Brigham and Women's Hospital), Jinglan Pei(Merck & Co., Inc., Rahway, NJ, USA (United States)), Hisao Ogawa(Kumamoto University Hospital), Edmond Chen(Merck & Co., Inc., Rahway, NJ, USA (United States)), Paul W. Armstrong(Canadian VIGOUR Centre), Gilles Montalescot(Maastricht University Medical Centre), Lixin Jiang(Fudan University), Marco Valgimigli(University of Bern), David J. Whellan(Thomas Jefferson University), Philip E. Aylward(Flinders Medical Centre), Witold Rużyłło(Institute of Cardiology), Giuseppe Ambrosio(University of Perugia), Peter Sinnaeve(Brigham and Women's Hospital), Robert F. Storey(University of Sheffield), Michael Hudson(Henry Ford Hospital), David J. Moliterno(University of Kentucky), Aycan Fahri Erkan(Ufuk University), Robert A. Harrington(Clinical Research Institute), Harvey D. White(University of Auckland), Lars Wallentin(Uppsala University), Sergio Leonardi(Policlinico San Matteo Fondazione), Frans Van de Werf(KU Leuven), John Strony(University Hospitals of Cleveland), Kurt Huber(Sigmund Freud Privatuniversität Wien), Claes Held(Uppsala University), A. Kilian(Merck & Co., Inc., Rahway, NJ, USA (United States)), Juan Carlos Prieto(University of Chile), Zhen Huang(Zhejiang Chinese Medical University), Matthias Pfisterer(University Hospital of Basel), Christoph Bode(University Medical Center Freiburg), Yuliya Lokhnygina(Clinical Research Institute), Rafael Díaz(Estudios Clínicos Latinoamérica), José Carlos Nicolau(Hospital São Paulo), Tyrus Rorick(Clinical Research Institute), A. Michael Lincoff(Cleveland Clinic)
Cited by 753
Related Papers
Dabigatran versus Warfarin in Patients with Atrial Fibrillation
|New England Journal of Medicine|2009|11.2k
Rivaroxaban versus Warfarin in Nonvalvular Atrial Fibrillation
|New England Journal of Medicine|2011|9.4k
Antiinflammatory Therapy with Canakinumab for Atherosclerotic Disease
|New England Journal of Medicine|2017|9.1k
Canagliflozin and Cardiovascular and Renal Events in Type 2 Diabetes
|New England Journal of Medicine|2017|7.7k
Ticagrelor versus Clopidogrel in Patients with Acute Coronary Syndromes
|New England Journal of Medicine|2009|7.1k